News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
<Results> BEONE MEDICINES (06160.HK) 1Q Net Profit USD227 million Surges 178x YoY; Raises FY2026 Revenue Guidance
BEONE MEDICINES (06160.HK) (ONC.US) announced its first-quarter results. Under US GAAP, total revenue rose 35.5% YoY to USD1.513 billion. Net profit surged 178x YoY to USD227 milli...
Reset
Send
The window will close in 5 seconds
<Results> BEONE MEDICINES (06160.HK) 1Q Net Profit USD227 million Surges 178x YoY; Raises FY2026 Revenue Guidance
Close
Recommend
5
Positive
6
Negative
1
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get Level 1 Real-Time Streaming!

BEONE MEDICINES (06160.HK)  -4.600 (-2.448%)    Short selling $71.84M; Ratio 22.812%   (ONC.US)      announced its first-quarter results. Under US GAAP, total revenue rose 35.5% YoY to USD1.513 billion. Net profit surged 178x YoY to USD227 million, mainly driven by revenue growth and improved operating leverage. Basic EPS was USD0.16.

Dividend History
Announce DateEventParticular
2026/02/26FinalNo Dividend
2025/11/063rd QuarterlyNo Dividend
2025/08/06InterimNo Dividend
2025/05/071st QuarterlyNo Dividend

During the quarter, global sales of BRUKINSA reached USD1.1 billion, up 38% YoY. Sales of TEVIMBRA (tislelizumab) amounted to USD206 million, up 20% YoY. GAAP gross margin was 89%, up 4 ppts, primarily due to a higher contribution of BRUKINSA in global sales and improved manufacturing efficiency.

Related News Citi Raises BeOne Medicines Ltd. (ONC.US) TP to USD453; 1Q26 Results Strong
The company updated its FY2026 guidance, revising total revenue to USD6.3 billionUSD6.5 billion from the previous USD6.2 billionUSD6.4 billion. GAAP operating profit is expected to range between USD750 million and USD850 million, while non-GAAP operating profit is projected at USD1.45 billionUSD1.55 billion. Gross margin is expected to remain at the high end of the 80% range. (de/d)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-05-14 12:25.) (Real-time Streaming US Stocks Quote; Except All OTC quotes are at least 15 minutes delayed.)
Auto-translated by AI
View Original Text
This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.

AASTOCKS Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.